Oncology

FDA Puts a Partial Clinical Hold on Adaptimmune’s Cancer Therapy Trial

PHILADELPHIA and OXFORD, United Kingdom, Aug. 03, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal …

Read More »

Novartis’ Investigational Breast Cancer Drug Receives FDA Breakthrough Therapy Designation

Basel, August 3, 2016 – Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LEE011 (ribociclib), in combination with letrozole, for the treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. LEE011 is a selective …

Read More »

Amgen and Advaxis Enter Cancer Immunotherapies Collaboration

THOUSAND OAKS, Calif. and PRINCETON, N.J., Aug. 2, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) today announced a global agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient’s immune system to respond against the unique …

Read More »

Over 750 Biomarkers Identified as Potentials for Early Cancer Screening Test

Researchers have identified 788 biomarkers in blood that could be used to develop an early stage cancer screening test for the general population. The study, led by the University of Sheffield, is the first to create a comprehensive list of relevant cancer blood biomarkers that have been researched in the …

Read More »

Jazz Enters Hematological Malignancies Licensing Deal with Pfenex

DUBLIN and SAN DIEGO, July 28, 2016 /PRNewswire/ — Jazz Pharmaceuticals plc(Nasdaq: JAZZ) and Pfenex Inc. (NYSE MKT: PFNX) today announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.  The agreement also includes an option for Jazz Pharmaceuticals …

Read More »

MEI Pharma’s Pracinostat Receives Breakthrough Therapy Designation from the FDA

SAN DIEGO, Aug. 1, 2016 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational drug Pracinostat in combination with azacitidine for …

Read More »

Takeda and Seattle Genetics Announce Positive Data from its Late-Stage Lymphoma Trial

BOTHELL, Wash., CAMBRIDGE, Mass. and OSAKA, Japan, August 1, 2016 – Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically …

Read More »

Triple-Therapy Patch Delivers Local Treatment, Prevents Recurrence in Colon Cancer Model

Investigators at Brigham and Women’s Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time. The new technique may allow clinicians to one day use diagnostic colonoscopy equipment to …

Read More »

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed GBM

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the National Comprehensive Cancer Network (NCCN) has recommended Optune as a standard treatment option for newly diagnosed glioblastoma (GBM) in its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. NCCN panel members designated Optune together with temozolomide …

Read More »

Bristol-Myers Squibb and Janssen Enter Immuno-Oncology Collaboration

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate Bristol-Myers Squibb’s Immuno-Oncology (I-O) agent Opdivo (nivolumab) and Janssen’s Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, expressing mesothelin and EGFRvIII (JNJ-64041757), in patients with non-small cell lung cancer (NSCLC). Opdivo …

Read More »